Anti-human immunodeficiency virus drug combination strategies.
about
The macrophage: a therapeutic target in HIV-1 infectionStructure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug designStructural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV proteaseStructure-Based Evaluation of C5 Derivatives in the Catechol Diether Series Targeting HIV-1 Reverse TranscriptasePrevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analoguesModelling of cytotoxicity data (CC50) of anti-HIV 1-[5-chlorophenyl) sulfonyl]-1H-pyrrole derivatives using calculated molecular descriptors and Levenberg-Marquardt artificial neural network.Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy.Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT.Role of murine leukemia virus reverse transcriptase deoxyribonucleoside triphosphate-binding site in retroviral replication and in vivo fidelity.Inhibition of human immunodeficiency virus type 1 replication prior to reverse transcription by influenza virus stimulation.Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy.Cytokines involved in Toxoplasmic encephalitis.The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replicationAnti-HIV activity of medicinal herbs: usage and potential development.Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase.Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV action.Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAVA novel mechanism of selectivity against AZT by the human mitochondrial DNA polymerase.Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery.Optimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophages.Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5.Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants.Some novel aminopropyl nucleoside phosphonates.Indolyl aryl sulphones as HIV-1 non-nucleoside reverse transcriptase inhibitors: synthesis, biological evaluation and binding mode studies of new derivatives at indole-2-carboxamide.Synthesis, solution conformation and anti-HIV activity of novel 3'-substituted-2',3'-dideoxy-5-hydroxymethyluridines and their 4,5-substituted analogues.Synthesis and antiviral evaluation of C-4-hydrazide derivatives of 2',3'-dideoxycytidine.The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in PortugalSynthesis and anti-HIV activity of [d4U]-[trovirdine analogue] and [d4T]-[trovirdine analogue] heterodimers as inhibitors of HIV-1 reverse transcriptase.A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failure.
P2860
Q26823236-EBCF627E-0E29-4D74-BADF-CA7D6018BCC4Q27620348-2CD72AAD-44B4-4F0F-A5F8-EDD693F99C45Q27621075-B5C5F28B-2167-4960-8FFF-A8E50389E833Q27680709-312E5B12-B16C-406A-A58B-8F767082D721Q28344476-99CB02D7-156F-4DDA-8E2E-A3E2747F4F8BQ33418728-C56448A2-D35D-40A5-A67A-55A03738084CQ33541775-A65D9096-92BB-4841-A146-63015A59780CQ33595278-D600E399-5D28-419E-BF4D-8851E77765B7Q33745946-DBB77A95-513A-40DA-8139-5410A0871614Q33787219-2EBF05DC-1713-46B9-97E3-9745E2CB36A7Q33804258-BADBD008-A6AE-4637-8326-03DCBC8445B2Q33982056-5895C8CC-1598-479C-A0E2-58687EDB231FQ34105601-EDEDE6DE-F122-4DAC-A7BE-6F10C36A9F79Q34141571-4E8D59CD-03D7-45F1-A750-5514B03568A3Q34231016-CDFA042A-E629-46DE-AB44-FB40DD3E6B99Q34299035-75FE3968-3CF6-4D87-9C3F-C98CDD605831Q35104511-A8CF886B-9C8C-4812-A2C7-15435DACF662Q36047499-EC65761F-BE49-458F-B5D8-67C3059E8CF3Q36280729-EF8B7A77-EA9F-454C-97F6-38FFB36C6853Q36328820-6F5A25C8-81E6-4FDA-BDF9-A93CA1A10B81Q37192494-90DF0DE8-2EC4-4D03-B368-279FE6E4C167Q37310990-252C31D8-23D6-4D00-8D27-9A0C10692BA9Q38164839-98D6E02C-3189-4BD4-A886-4F9379D45CBDQ39456107-A80EE0D2-27BF-4640-831B-75D30AE6F353Q39477865-61397AE8-4EA7-42ED-9DDB-70D10183EE59Q39603927-B4BD03A8-A579-4654-8DA3-D97BBAEC6804Q40037913-BF3970BF-96A9-4A51-A6EB-0943A94A6447Q40220119-45232A03-66D7-4FA5-8DF4-C4CDF64101E6Q40629852-E7E68D46-71E0-457A-8015-D30590DDB43FQ40779750-6730ACE0-45D5-4C82-9F2E-5570B206A4F3Q42742963-F261916C-7854-4136-A95B-7CA110B3E36DQ44250812-0E82D48D-C4C1-4B32-8219-4344AF7B497CQ52025965-E6F4407C-DD37-4DA3-9A93-86D6621E3CAF
P2860
Anti-human immunodeficiency virus drug combination strategies.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Anti-human immunodeficiency virus drug combination strategies.
@en
Anti-human immunodeficiency virus drug combination strategies.
@nl
type
label
Anti-human immunodeficiency virus drug combination strategies.
@en
Anti-human immunodeficiency virus drug combination strategies.
@nl
prefLabel
Anti-human immunodeficiency virus drug combination strategies.
@en
Anti-human immunodeficiency virus drug combination strategies.
@nl
P2860
P1476
Anti-human immunodeficiency virus drug combination strategies.
@en
P2093
E De Clercq
K Van Vaerenbergh
P2860
P304
P356
10.1177/095632029800900301
P577
1998-05-01T00:00:00Z